SOPHiA Reports Strong Q3 2026 Growth Driven by U.S. Revenue and Liquid Biopsy Adoption
SOPHiA (SOPH) reported strong third-quarter 2026 results, projecting full-year revenue at the upper end of its $94 million to $96 million guidance range. The company saw significant momentum in the United States, where revenue grew 41% year-over-year as hospitals increasingly adopt in-house genetic testing capabilities. This shift is driven by declining sequencing costs and improved reimbursement rates. Global adoption of liquid biopsy services more than doubled year-over-year to 4,200 analyses, signaling a major growth catalyst for international markets. Additionally, the company demonstrated improving operating leverage, with adjusted EBITDA losses narrowing by 31% compared to the previous year. With $94 million in cash reserves and a net new business pipeline exceeding $100 million, SOPHiA is positioning itself toward long-term profitability through scalable AI-native software.

Tickers: $SOPH
Topics: genetic data analysis healthcare technology quarterly earnings revenue guidance